Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This phase 2 randomised clinical trial will investigate the activity and safety of adding
Lu-PSMA to enzalutamide in patients with metastatic castrate resistant prostate cancer
(mCRPC) not previously treated with chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Collaborators:
Astellas Pharma Inc Australian Nuclear Science and Technology Organisation Endocyte National Health and Medical Research Council, Clinical Trials Centre Prostate Cancer Research Alliance